| 摘要 |
<p>The subject matter of the invention relates to a novel composition of 3,4-diaminopyridine (3,4-DAP) rendering same stable and homogeneous, prepared in the form of a capsule for the treatment and control of paraneoplastic Lambert-Eaton myasthenic syndrome, characterised by muscle fatigability associated with neurovegetative disorders. Said drug is used in fatigability associated with multiple sclerosis, botulism and congenital myasthenic syndromes and Alzheimer's disease. The novelty also relates to the dosing protocol of the active agent and of the carriers. In the novel 3,4-DAP composition, the mixture is supplied in the form of a capsule, tablet or oral suspension, or other dosage forms.</p> |
